AOF1抗体 新品

+ +

•  

   

     Black line: Control Antigen (100 ng); Purple line: Antigen(10ng); Blue line: Antigen (50 ng); Red line: Antigen (100 ng);    

  
  

•  

   

     Immunofluorescence analysis of HeLa cells using AOF1 mouse mAb. Blue: DRAQ5 fluorescent DNA dye. Red: Actin filaments have been labeled with Alexa Fluor- 555 phalloidin.    

  
  

•  

   

     Immunofluorescence analysis of HeLa cells using AOF1 mouse mAb (green). Blue: DRAQ5 fluorescent DNA dye. Red: Actin filaments have been labeled with Alexa Fluor- 555 phalloidin. Secondary antibody from Fisher (Cat#: 35503)    

  
  

•  

   

     Flow cytometric analysis of HeLa cells using AOF1 mouse mAb (green) and negative control (red).    

  
  

•  

   

     Immunohistochemical analysis of paraffin-embedded human esophageal cancer tissues using AOF1 mouse mAb with DAB staining.    

  
  

•  

   

     Immunohistochemical analysis of paraffin-embedded human rectum cancer tissues using AOF1 mouse mAb with DAB staining.    

  
  

The AOF1 antibody targets the protein Amine Oxidase Flavin-Containing 1 (AOF1), also known as Lysine-Specific Demethylase 1 (LSD1/KDM1A). AOF1 is a flavin-dependent monoamine oxidase that plays a critical role in epigenetic regulation by catalyzing the demethylation of histone H3 lysine 4 (H3K4) and lysine 9 (H3K9), thereby modulating chromatin structure and gene expression. It is essential for embryonic development, cell differentiation, and proliferation. Dysregulation of AOF1 has been implicated in cancers, neurological disorders, and other diseases due to its role in oncogenic pathways and cellular identity maintenance.

AOF1 antibodies are widely used in research to investigate its expression, localization, and interaction partners in various biological contexts. They are employed in techniques such as Western blotting, immunoprecipitation, chromatin immunoprecipitation (ChIP), and immunofluorescence to study AOF1's function in epigenetic mechanisms. These antibodies are critical for elucidating how AOF1 contributes to transcriptional repression, stem cell pluripotency, and tumor progression. Available as monoclonal or polyclonal variants, AOF1 antibodies are typically validated for specificity in human, mouse, or rat samples. Their development has advanced studies on targeted therapies, particularly in cancer, where AOF1 inhibitors are explored for their potential to reverse aberrant epigenetic modifications.